The lessons learned from the clinical application of epidermal growth factor receptor tyrosine kinase inhibitors provide important insights for lung cancer therapies. What approaches might circumvent the rapid acquisition of resistance and increase the efficacy of targeted therapies in lung cancer and other epithelial cancers?
- Sreenath V. Sharma
- Daphne W. Bell
- Daniel A. Haber